Michael Feldman

Michael Feldman leads TCR discovery efforts at Adaptimmune Therapeutics, developing the proprietary platform for identifying and affinity-enhancing T cell receptors targeting tumor-associated antigens including the MAGE-A4 antigen targeted by afamitresgene autoleucel. His work on understanding TCR-peptide-MHC interactions has enabled rational engineering of TCRs with improved affinity while maintaining specificity and avoiding cross-reactivity. He has contributed to building the computational and experimental tools used to screen billions of TCR variants for optimal therapeutic candidates.